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competing risksIn the analysis of time-to-event end points, a competing
risk (competing cause or competing event) may be defined
as ‘‘an event whose occurrence either precludes the occur-
rence of another event under examination or fundamen-
tally alters the probability of occurrence of this other
event’’ [1]. Recent articles in the Journal of Clinical
Epidemiology have shown that KaplaneMeier (KM)
estimates biased from competing risks are commonly pub-
lished in leading medical journals [2,3] and overestimated
event risk by over 10% in approximately one-third of
studies susceptible to competing events [3]. Thus, they
recommend the use of the cumulative incidence function
instead of KM to estimate risk in the presence of
competing events [2,3].
In this context, we compared the cumulative incidence
of second primary cancers (SPCs) estimated using different
methods: (1) incidence proportion, calculated as ‘‘the pro-
portion of a closed population at risk that becomes diseased
within a given period of time’’ [4] (5 years for the entire
sample and 10 years for a subsample); (2) 1-KM; and (3)
cumulative incidence function introduced by Kalbfleisch
and Prentice [5], which takes into account competing
events. A population-based cohort of gastric first primary
cancers (FPCs) from the North Region Cancer Registry of
Portugal, diagnosed in 2000e2006, was followed to
December 31, 2011, until the diagnosis of an SPC, or death,
whichever occurred first [6]. Whenever more than two pri-
mary cancers were observed, only the first SPC was consid-
ered, regardless of time elapsed since the FPC. Data were
defined to be survival time data with the occurrence of an
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0895-4356/ 2017 Elsevier Inc. All rights reserved.competing event, as its occurrence hinders the incidence
of an SPC.
As depicted in Fig. 1, the cumulative incidence of SPCs
was similar between the different methods for the first few
months; however, over time, the cumulative incidence esti-
mates obtained with 1-KM tended to be higher and less pre-
cise than those calculated using the incidence proportion or
competing risks method. Compared to estimates obtained
with the competing risks method, 1-KM overestimated cu-
mulative incidence ranging from 25% higher at 1 year to
150% higher at 10 years, with respective differences
ranging from þ0.4 to þ7.2. Conversely, the competing
risks method provided estimates similar to those calculated
using the incidence proportion, ranging from 20% lower at
1 year to only 17% higher at 10 years, with corresponding
differences between 0.4 and þ0.7.
To further illustrate the extent to which cumulative inci-
dence estimates obtained from 1-KM and competing risks
differ considering various proportions of competing events,
we performed a stratified analysis by age at FPC diagnosis.
The increase of the 1-KMebased risk compared to the
competing risks method got larger as the proportion of out-
comes that are competing events increased. According to
age (!70 and 70 years), a higher percentage of deaths
was found among older patients (81.7% vs. 63.2%), while
the proportion of SPCs was lower in older patients (4.5%
vs. 5.0%). These disparities were reflected in nearly
twofold and threefold higher estimates of SPCs obtained
from 1-KM for younger (10.9% vs. 5.3%) and older pa-
tients (13.9% vs. 4.3%), respectively. In general, the bias
observed in 1-KM depended on the incidence rates for
both the event of interest and the competing event, and
may lead to a considerably large overestimation.
When analyzing competing risks data, it is important to
realize the possible contributions of sound statistical meth-
odology for the adequate exploration of the data. The use of
the standard 1-KM to estimate cause-specific cumulative
probability, which assumes a one-to-one correspondence
between rate and risk, can lead to an inflated estimate of
the proportion of patients who are at risk of failure at a spe-
cific time. This results in an overestimation of the risk [1],
though the extent of the bias may not always be immedi-
ately perceived.
Currently, quantifying the risk of SPCs is of particular
importance because the number of cancer survivors con-
tinues to grow, due to more frequent early detection as
well as advances in therapy [7] reaching an estimated
32.5 million 5-year survivors worldwide in 2012 [8].
Fig. 1. Cumulative incidence estimates of second primary cancers to December 31, 2011, using the incidence proportion (5 and 10 years*),
1-KaplaneMeier, and competing risks methods. *Only including those diagnosed in 2000e2001, which have 10 years of follow-up (81 second
primary cancers in 1995 gastric first primary cancer patients). 95% CI, 95% confidence interval; SPC, second primary cancer).
2 Letter to the Editor / Journal of Clinical Epidemiology - (2017) -The present worked example shows that, with the occur-
rence of competing events, e.g., death, there is an
evident overestimation of cumulative incidence by 1-
KM, precluding its use to estimate the long-term probabil-
ity of SPCs.
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